In the context of the post-genomic era, where targeted oncological therapies like monoclonal antibodies (mAbs) and tyrosine-kinase inhibitors (TKIs) are gaining prominence, this study investigates whether these therapies can enhance survival for lung carcinoma patients with specific genetic mutations—EGFR-amplified and ALK-rearranged mutations. Prior to this study, no research series had explored how these mutations influence patient survival in cases of surgical lung brain metastases (BMs). Through a multi-site retrospective analysis, the study examined patients who underwent surgical resection for BM arising from primary lung cancer at Emory University Hospital from January 2012 to May 2022. The mutational statuses were determined from brain tissue biopsies, and survival analyses were conducted. Results from 95 patients (average age: 65.8 ± 10.6) showed that while 6.3% had anaplastic lymphoma kinase (ALK)-rearranged mutations and 20.0% had epidermal growth factor receptor (EGFR)-amplified mutations—with 9.5% receiving second-line therapies—these mutations did not significantly correlate with overall survival. Although the sample size of patients receiving targeted therapies was limited, the study highlighted improved overall survival and progression-free survival rates compared to earlier trials, suggesting advancements in systemic lung metastasis treatment. The study suggests that as more targeted therapies emerge, the prospects for increased overall survival and progression-free survival in lung brain metastasis patients will likely improve.
在后基因组时代背景下，单克隆抗体（mAbs）和酪氨酸激酶抑制剂（TKIs）等靶向肿瘤治疗日益受到重视。本研究旨在探讨这些疗法能否提高携带特定基因突变（EGFR扩增和ALK重排）的肺癌患者生存率。此前尚无研究系统探讨这些突变如何影响肺源性脑转移瘤（BMs）手术患者的生存情况。通过多中心回顾性分析，本研究纳入2012年1月至2022年5月在埃默里大学医院接受原发性肺癌脑转移灶手术切除的患者，通过脑组织活检确定基因突变状态并进行生存分析。对95例患者（平均年龄65.8±10.6岁）的研究结果显示：6.3%存在间变性淋巴瘤激酶（ALK）重排突变，20.0%存在表皮生长因子受体（EGFR）扩增突变，其中9.5%接受二线治疗，但这些突变与总生存期无显著相关性。尽管接受靶向治疗的患者样本量有限，但与早期试验相比，本研究观察到总生存期和无进展生存期的改善，提示全身性肺转移治疗取得进展。研究表明随着更多靶向疗法的出现，肺源性脑转移患者的总生存期和无进展生存期有望进一步提升。
肿瘤(癌症)患者之家